A phase 2 trial of daratumumab monotherapy for patients with newly diagnosed cardiac stage IIIb AL amyloidosis.

In 30 seconds

This prospective, multicentre phase 2 trial evaluated daratumumab monotherapy in previously untreated patients with measurable AL amyloidosis and advanced cardiac stage IIIB disease; patients with inadequate response after three cycles could add bortezomib and dexamethasone. Among 40 enrolled patients, the 6-month overall survival rate was 65% (95% confidence interval, 48.2-77.6), and median overall survival was 10.4 months. By 6 months, 75% had achieved a partial hematologic response or better, while the cardiac response rate was 30%. The authors considered treatment feasible and well tolerated.

Key findings

• The 6-month overall survival rate was 65% (95% confidence interval, 48.2-77.6); median overall survival was 10.4 months.
• By 6 months, 75% achieved a partial hematologic response or better, including 47.5% with very good partial response or better and 12.5% with complete response.
• The median time to first hematologic response was 1 week, and to best response was 2.3 months.
• Cardiac response at 6 months was 30%; common serious adverse events included cardiac failure (25%), sudden cardiac death (10%), and acute kidney injury (7.5%).

Why it matters

Stage IIIB cardiac AL amyloidosis is a high-risk setting with limited treatment options. This trial provides prospective evidence that daratumumab-based treatment can produce rapid hematologic responses in this population, alongside reported survival and cardiac response outcomes. The serious cardiac and renal events also underscore the substantial clinical risk in this group and the importance of interpreting response alongside safety.

What to keep in mind

The trial was a phase 2 study with 40 patients and no concurrent comparator. The abstract’s comparison of survival with historical cohorts does not establish comparative treatment benefit.